{"id":"NCT01148225","sponsor":"AbbVie","briefTitle":"A Study of the Long-term Safety and Efficacy of Adalimumab in Subjects With Intermediate-, Posterior-, or Pan-uveitis","officialTitle":"A Multicenter Open-Label Study of the Long-term Safety and Efficacy of the Human Anti-TNF Monoclonal Antibody Adalimumab in Subjects With Non-infectious Intermediate Uveitis, Posterior Uveitis, or Panuveitis","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2010-11-23","primaryCompletion":"2018-05-21","completion":"2018-05-21","firstPosted":"2010-06-22","resultsPosted":"2019-04-04","lastUpdate":"2021-07-12"},"enrollment":424,"design":{"allocation":"NA","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Uveitis"],"interventions":[{"type":"DRUG","name":"adalimumab","otherNames":["ABT-D2E7","Humira"]}],"arms":[{"label":"Adalimumab","type":"OTHER"}],"summary":"The purpose of this study is to evaluate the long term efficacy and safety of adalimumab participants with non-infectious intermediate-, posterior- or pan-uveitis.","primaryOutcome":{"measure":"Number of Participants With Adverse Events","timeFrame":"Baseline to Final Visit (up to 366 weeks)","effectByArm":[{"arm":"Adalimumab","deltaMin":398,"sd":null}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":1,"exclusionCount":7},"locations":{"siteCount":0,"countries":[]},"refs":{"pmids":["33157077"],"seeAlso":["http://rxabbvie.com"]},"adverseEventsSummary":{"seriousAny":{"events":101,"n":424},"commonTop":["UVEITIS","NASOPHARYNGITIS","ARTHRALGIA","HEADACHE","URINARY TRACT INFECTION"]}}